Recent Updates
Recently added Catalysts

Anktiva

Phase 2

Long COVID | Small molecule | Infectious Disease |ImmunityBio, Inc.|Last Updated: May 13, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07123727A Study to Examine Anktiva for the Treatment of COVID-19.PHASE2 RECRUITING 40 — — Sep 4, 2025Jul 1, 2026May 13, 20261 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.
Through 30 days post final study drug administration.
Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration.
Through 30 days post final study drug administration.
Incidence of serious adverse events (SAEs) through 30 days post final study drug administration.
Through 30 days post final study drug administration.
Incidence of abnormal changes in safety laboratory tests (CBC and CMP).
Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as temperature in degrees Fahrenheit.
Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as heart rate in beats per minute.
Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as blood pressure in millimeters of mercury (mmHg).
Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as respiratory rate in breaths per minute.
Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as oxygen saturation in percentage.
Through the end of the study treatment period (approximately 75 days).
Secondary Endpoints
Percent increase or decrease change in the Absolute lymphocyte count (as measured on CBC) from Screening to End Of Study with various timepoints.
Through the end of the study treatment period (approximately 75 days).
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
N-803EXPERIMENTAL -
Interventions
NameTypeDescription
AnktivaDRUG600ug of NAI administered subcutaneously
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Age ≥ 18 and \< 70 years. * History of at least one SARS-CoV-2 infection, defined as report of a positive nucleic acid amplification test (NAAT) and/or a positive SARS-CoV-2 antigen rapid diagnostic test (RDT). Those with only suspected but unconfirmed infections are not eligi...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -COVID-19 39 trials
CompanyTickerTrialsLead PhaseDrugs
Pfizer Inc.PFE10PHASE3ibuzatrelvir, remdesivir, nirmatrelvir, ritonavir, COVID-19 Vaccine
BioNTech SE Sponsored ADRBNTX3PHASE3BNT162b2, BNT162b2 Vaccine, Bivalent BNT162b2 3 microgram dose, Bivalent BNT162b2 6 microgram dose, Bivalent BNT162b2 10 microgram dose
Merck & Co., Inc.MRK1PHASE3Molnupiravir
Invivyd, Inc.IVVD2PHASE3VYD2311-SD, VYD2311-MD, VYD2311
Vanda Pharmaceuticals Inc.VNDA1PHASE3Tradipitant
BioVie Inc. Class ABIVI1PHASE2NE3107
ImmunityBio IncIBRX2PHASE2Anktiva, N-803
Traws Pharma, Inc.TRAW1PHASE2Ratutrelvir non-randomised, Paxlovid, Ratutrelvir
GeoVax Labs, Inc.GOVX1PHASE2COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Unity Health TorontoUBX1PHASE3Paxlovid, Antioxidant
Moderna, Inc.MRNA1 — SPIKEVAX Bivalent BA.1, SPIKEVAX XBB.1.5, SPIKEVAX JN.1
Abbott LaboratoriesABT1NAUndisclosed
Design Therapeutics, Inc.DSGN1EARLY_PHASE1COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
Jade Biosciences, Inc.JBIO1NAUndisclosed
Structure Therapeutics, Inc. Sponsored ADRGPCR1NAUndisclosed
Co-Diagnostics, Inc.CODX1 — Undisclosed
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07123727primaryCompletionDate: changed
LOWMay 24, 2026NCT07123727studyFirstPostDate: changed